Tucidinostat
Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Allogeneic Hematopoietic Cell Transplantation (HCT) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib The First Affiliated Hospital of Soochow University | Phase 3 | B |
Gilteritinib The First Affiliated Hospital of Soochow University | Phase 3 | B |
Rapamycin Stanford University | Phase 1 | CC |
cd4+cd25+ regulatory t cells Stanford University | Phase 1 | CC |
TACROLIMUS Stanford University | Phase 1 | CC |
View all 15 →
Same molecule, other indications
Tucidinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →